At a glance
- Originator Aventis
- Class Antibacterials; Fluoroquinolones; Naphthyridines; Small molecules
- Mechanism of Action DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 23 Dec 1999 Rhône-Poulenc Rorer has merged with Hoechst Marion Roussel to form Aventis Pharma
- 04 Jun 1997 Preclinical development for Bacterial infections in USA (Unknown route)